Is mivamutide injection available on the international market?

Mifamurtide injection (Mifamurtide) has been approved for marketing in the international market, especially in Europe, where it entered clinical use earlier. The drug was approved by the European Medicines Agency (EMA) in 2009 for the treatment of non-metastatic, surgically resectable high-grade osteosarcoma. It is usually used in combination with standard postoperative chemotherapy regimens and is suitable for patients aged 2 to 30 years. The marketed trade name is Mepact, and the approval also marks it as the first immune-activating drug in Europe for the adjuvant treatment of osteosarcoma.

Outside Europe, the marketing status of mivamutide varies depending on national regulations and market strategies. Although the U.S. Food and Drug Administration (FDA) has reviewed the clinical data of the drug, it has not yet received formal marketing approval in the United States, and therefore has not been commercialized in the U.S. market. Some Asia-Pacific and Latin American countries are providing such drugs through "orphan drug import" or "clinical emergency use" pathways. Especially in medical systems that lack targeted treatments for osteosarcoma, milvamuttide provides more treatment options for pediatric patients.

In addition, because this drug mainly targets high-risk osteosarcoma in children, a rare disease, its market size is relatively limited, but the clinical demand is very urgent, so it is often included in the "orphan drug" policy support object and enjoys market exclusivity and tax incentives. This strategy has also prompted many European countries, including Italy, Germany, and France, to include it in their national medical insurance systems or rare disease relief frameworks.

In summary, mivamutin injection has been launched in international markets such as Europe, and has a unique position in the treatment of high-grade osteosarcoma. As the global policy on rare disease drugs gradually opens up, its accessibility in other regional countries is expected to continue to expand, filling the clinical gap in the treatment of adolescent osteosarcoma.

Reference materials:https://en.wikipedia.org/wiki/Mifamurtide